title: Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
abstract: OBJECTIVE
  To evaluate the effect of natalizumab on progression of brain atrophy in multiple sclerosis (MS) patients and to search for a clinical or radiological marker of progression of brain atrophy.
  
  
  METHODS
  We retrospectively recorded demographic and clinical data, as well as the corpus callosum index (CCI) using MRI, in MS patients treated with natalizumab for 1-4 years.
  
  
  RESULTS
  In the study population (n = 29), baseline mean CCI was 0.37 ± 0.04 and final CCI 0.36 ± 0.04. 17 patients did not develop brain atrophy during follow-up. There was no statistically significant relationship between progression of atrophy and clinical and radiological parameters.
  
  
  CONCLUSIONS
  Natalizumab may have a neuroprotective effect.
authors.affiliation: Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.
authors.forename: Eva Costa
authors.initials: EC
authors.lastname: Arpín
authors.affiliation: Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.
authors.forename: Tania García
authors.initials: TG
authors.lastname: Sobrino
authors.affiliation: Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.
authors.forename: Clara Domínguez
authors.initials: CD
authors.lastname: Vivero
authors.affiliation: Department of Neurology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain.
authors.forename: María
authors.initials: M
authors.lastname: del Campo Amigo Jorrín
authors.affiliation: Department of Neurology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain.
authors.forename: Ana Rodríguez
authors.initials: AR
authors.lastname: Regal
authors.affiliation: Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.
authors.forename: José Prieto
authors.initials: JP
authors.lastname: González
authors.affiliation: Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.
authors.forename: Manuela Lema
authors.initials: ML
authors.lastname: Bouzas
mesh_terms: D000328:Adult; D001284:Atrophy / Q000150:complications / Q000517:prevention & control*; D001921:Brain / Q000187:drug effects* / Q000473:pathology*; D003337:Corpus Callosum / Q000187:drug effects / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications* / Q000188:drug therapy; D000069442:Natalizumab / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D007155:Immunologic Factors; D000069442:Natalizumab
keywords: brain atrophy; corpus callosum index; multiple sclerosis; natalizumab